{"product_id":"international-myeloma-society-practical-insights-in-and-translational-aspects-of-novel-immune-therapies-in-multiple-myeloma-2025","title":"International Myeloma Society Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025","description":"\u003cdiv class=\"group-header field-group-div clearfix\"\u003e\r\n\u003cdiv class=\"group-header-inner field-group-div\"\u003e\r\n\u003cdiv class=\"group-course-header-right field-group-div\"\u003e\r\n\u003cdiv class=\"field field-name-title field-type-ds field-label-hidden\"\u003e\r\n\u003cdiv class=\"field-items\"\u003e\r\n\u003cdiv class=\"field-item even\"\u003e\r\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\r\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\r\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\r\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\r\n\u003cdiv class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_3_5 3_5 fusion-flex-column\"\u003e\r\n\u003cdiv class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"\u003e\r\n\u003cdiv class=\"fusion-text fusion-text-2\"\u003e\r\n\u003cdiv class=\"cme-gallery\"\u003e\r\n\u003cdiv class=\"container\" data-testid=\"cme-gallery\"\u003e\r\n\u003cdiv class=\"grid col-span-full mt-3 lg:mt-0\"\u003e\r\n\u003cdiv class=\"cme-gallery__description has-rich-text col-span-full lg:col-span-9 type-body has-rich-text\"\u003e\r\n\u003ch1\u003eInternational Myeloma Society (IMS) Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025 (Videos)\u003c\/h1\u003e\r\n\u003ch2\u003eComprehensive Updates in CAR T-Cell Therapy, Bispecific Antibodies, Antibody-Drug Conjugates, BCMA-Targeted Therapies, and Precision Immunotherapy for Multiple Myeloma\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eAdvance your understanding of next-generation immunotherapy with the \u003cstrong\u003eInternational Myeloma Society (IMS) Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025\u003c\/strong\u003e, an advanced continuing medical education (CME) program dedicated to the rapidly evolving landscape of immune-based treatments for multiple myeloma. This comprehensive educational workshop provides clinicians with practical guidance for integrating novel immunotherapies into clinical practice while addressing patient selection, toxicity management, translational science, and real-world treatment strategies.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eHeld on \u003cstrong\u003eOctober 27, 2025\u003c\/strong\u003e, in conjunction with the \u003cstrong\u003eDGHO Annual Meeting\u003c\/strong\u003e, the program is offered both \u003cstrong\u003evirtually and in person\u003c\/strong\u003e at the \u003cstrong\u003eCongress-Centrum Koelnmesse in Cologne, Germany\u003c\/strong\u003e. International experts review the latest clinical evidence supporting antibody-drug conjugates (ADCs), bispecific T-cell engagers (TCEs), and chimeric antigen receptor (CAR) T-cell therapies, with particular emphasis on \u003cstrong\u003eB-cell maturation antigen (BCMA)-targeted treatments\u003c\/strong\u003e for patients with relapsed or refractory multiple myeloma.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDesigned to bridge the educational gap between specialized CAR T treatment centers and community oncology practices, this workshop equips healthcare professionals with practical, evidence-based approaches for implementing advanced immune therapies while optimizing patient safety and treatment outcomes.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eProduct Details\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eProvider:\u003c\/strong\u003e International Myeloma Society (IMS)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eConference Date:\u003c\/strong\u003e October 27, 2025\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e Congress-Centrum Koelnmesse, Cologne, Germany\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Hybrid (In-Person \u0026amp; Virtual) – Videos\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEducational Level:\u003c\/strong\u003e Advanced\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eCourse Overview\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe treatment landscape for multiple myeloma has undergone remarkable transformation with the introduction of highly effective immune-based therapies. Novel agents targeting \u003cstrong\u003eBCMA\u003c\/strong\u003e, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates, have significantly improved outcomes for patients with relapsed or refractory disease while introducing new challenges related to patient selection, toxicity management, supportive care, and treatment sequencing.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis comprehensive educational program provides clinicians with practical guidance for incorporating these innovative therapies into everyday oncology practice. Faculty review current clinical trial data, translational research, mechanisms of immune activation, treatment eligibility, adverse event recognition, and multidisciplinary patient management strategies.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants gain a practical understanding of how novel immune therapies are reshaping the management of multiple myeloma while learning evidence-based approaches that can be applied across both academic and community oncology settings.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhat You'll Learn\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eAfter completing this course, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eIdentify patients who are appropriate candidates for CAR T-cell therapy and bispecific antibody treatment.\u003c\/li\u003e\r\n \t\u003cli\u003eDifferentiate the mechanisms of action of CAR T cells, bispecific T-cell engagers, and antibody-drug conjugates.\u003c\/li\u003e\r\n \t\u003cli\u003eApply evidence-based strategies for selecting immune-based therapies in relapsed and refractory multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize and manage treatment-related toxicities associated with novel immunotherapies.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate BCMA-targeted therapies into individualized treatment plans.\u003c\/li\u003e\r\n \t\u003cli\u003eImprove coordination between referral centers and community oncology practices.\u003c\/li\u003e\r\n \t\u003cli\u003eApply translational research findings to optimize patient outcomes.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eComprehensive Topics Covered\u003c\/h1\u003e\r\n\u003ch2\u003eMultiple Myeloma Immunotherapy\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview the latest advances in immune-based treatment strategies that are transforming the management of multiple myeloma.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eImmune therapies\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision oncology\u003c\/li\u003e\r\n \t\u003cli\u003ePersonalized treatment\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment sequencing\u003c\/li\u003e\r\n \t\u003cli\u003eClinical decision-making\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging therapeutic strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eCAR T-Cell Therapy\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDevelop a comprehensive understanding of CAR T-cell therapy from patient referral through treatment and long-term follow-up.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCAR T-cell manufacturing\u003c\/li\u003e\r\n \t\u003cli\u003ePatient eligibility\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment preparation\u003c\/li\u003e\r\n \t\u003cli\u003eClinical outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eLong-term monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eResponse assessment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty discuss practical implementation strategies for both referral and treatment centers.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eBispecific T-Cell Engagers (TCEs)\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview current evidence supporting bispecific antibodies and their growing role in relapsed and refractory multiple myeloma.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eT-cell engagers\u003c\/li\u003e\r\n \t\u003cli\u003eMechanisms of action\u003c\/li\u003e\r\n \t\u003cli\u003eClinical trial updates\u003c\/li\u003e\r\n \t\u003cli\u003ePatient selection\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment sequencing\u003c\/li\u003e\r\n \t\u003cli\u003eResponse evaluation\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eAntibody-Drug Conjugates (ADCs)\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eLearn how antibody-drug conjugates are incorporated into modern myeloma treatment algorithms.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAntibody-drug conjugates\u003c\/li\u003e\r\n \t\u003cli\u003eBCMA-targeted therapies\u003c\/li\u003e\r\n \t\u003cli\u003eClinical efficacy\u003c\/li\u003e\r\n \t\u003cli\u003eSafety monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eAdverse event management\u003c\/li\u003e\r\n \t\u003cli\u003ePatient selection\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eBCMA-Targeted Therapies\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eExplore the expanding role of \u003cstrong\u003eB-cell maturation antigen (BCMA)\u003c\/strong\u003e as one of the most important therapeutic targets in modern multiple myeloma treatment.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty review:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBCMA biology\u003c\/li\u003e\r\n \t\u003cli\u003eTargeted immunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eClinical applications\u003c\/li\u003e\r\n \t\u003cli\u003eResistance mechanisms\u003c\/li\u003e\r\n \t\u003cli\u003eFuture therapeutic developments\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eToxicity Management\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eGain practical strategies for recognizing, monitoring, and managing adverse events associated with advanced immune therapies.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCytokine release syndrome (CRS)\u003c\/li\u003e\r\n \t\u003cli\u003eImmune-related toxicities\u003c\/li\u003e\r\n \t\u003cli\u003eNeurotoxicity\u003c\/li\u003e\r\n \t\u003cli\u003eInfection prevention\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive care\u003c\/li\u003e\r\n \t\u003cli\u003ePost-treatment monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eTranslational Medicine\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eBridge laboratory discoveries with clinical practice through expert discussions of translational research and future therapeutic developments.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eTranslational oncology\u003c\/li\u003e\r\n \t\u003cli\u003eBiomarker development\u003c\/li\u003e\r\n \t\u003cli\u003eImmune microenvironment\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision medicine\u003c\/li\u003e\r\n \t\u003cli\u003eFuture clinical trials\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eCommunity Oncology Integration\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eLearn practical approaches for improving collaboration between specialized cellular therapy centers and community oncology practices to ensure timely referral, appropriate patient selection, and continuity of care.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eLearning Objectives\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUpon completion of this educational activity, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eIdentify patients who may benefit from novel immune-based therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eDifferentiate CAR T-cell therapies, bispecific T-cell engagers, and antibody-drug conjugates.\u003c\/li\u003e\r\n \t\u003cli\u003eApply evidence-based treatment selection strategies for relapsed and refractory multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize and manage treatment-related toxicities associated with immune therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate BCMA-targeted therapies into multidisciplinary patient care.\u003c\/li\u003e\r\n \t\u003cli\u003eApply translational research findings to improve treatment outcomes.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eEducational Highlights\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMultiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eCAR T-Cell Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eBCMA-Targeted Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eBispecific Antibodies\u003c\/li\u003e\r\n \t\u003cli\u003eBispecific T-Cell Engagers\u003c\/li\u003e\r\n \t\u003cli\u003eAntibody-Drug Conjugates\u003c\/li\u003e\r\n \t\u003cli\u003eImmunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eTranslational Medicine\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision Oncology\u003c\/li\u003e\r\n \t\u003cli\u003eHematologic Malignancies\u003c\/li\u003e\r\n \t\u003cli\u003ePlasma Cell Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eToxicity Management\u003c\/li\u003e\r\n \t\u003cli\u003eCytokine Release Syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eNeurotoxicity\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive Care\u003c\/li\u003e\r\n \t\u003cli\u003eCommunity Oncology\u003c\/li\u003e\r\n \t\u003cli\u003eCase-Based Learning\u003c\/li\u003e\r\n \t\u003cli\u003eExpert Faculty\u003c\/li\u003e\r\n \t\u003cli\u003eContinuing Medical Education (CME)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy This Course Stands Out\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003eInternational Myeloma Society Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025\u003c\/strong\u003e provides one of the most practical educational updates available on modern immune-based treatment strategies for multiple myeloma. Rather than focusing exclusively on clinical trial data, the program emphasizes real-world implementation of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, helping clinicians confidently integrate these rapidly evolving therapies into routine patient care while effectively managing associated toxicities.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eTarget Audience\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis educational activity is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHematologists\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Oncologists\u003c\/li\u003e\r\n \t\u003cli\u003eHematopathologists\u003c\/li\u003e\r\n \t\u003cli\u003eSurgical Pathologists\u003c\/li\u003e\r\n \t\u003cli\u003eInfectious Disease Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eOphthalmologists\u003c\/li\u003e\r\n \t\u003cli\u003eNeurologists\u003c\/li\u003e\r\n \t\u003cli\u003eImmunologists\u003c\/li\u003e\r\n \t\u003cli\u003eHematology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eOncology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eNurse Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003ePhysician Assistants\u003c\/li\u003e\r\n \t\u003cli\u003eHealthcare Professionals involved in the treatment of multiple myeloma and plasma cell disorders\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy Choose This Course?\u003c\/h1\u003e\r\nWhether you practice hematology, medical oncology, pathology, or immunology, the \u003cstrong\u003eInternational Myeloma Society Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025\u003c\/strong\u003e delivers an exceptional evidence-based review of the latest immune therapies transforming multiple myeloma treatment. Combining internationally recognized faculty, translational science, practical treatment strategies, toxicity management, and multidisciplinary care, this program provides clinicians with the knowledge needed to confidently implement next-generation immunotherapies in modern clinical practice.\r\n\u003ch3 class=\"product_title entry-title\"\u003e\u003cspan style=\"font-size: 20.16px;\"\u003eTopics\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003cul data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003e\u003cb data-path-to-node=\"8,0,0\" data-index-in-node=\"0\"\u003eAdvances in Diagnostics\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"8,0,2\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-95\" data-path-to-node=\"8,0,2,0,0\"\u003e\u003cspan data-path-to-node=\"8,0,2,0,0,0\"\u003eBreakout Lesions\/EMD\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-96\" data-path-to-node=\"8,0,2,1,0\"\u003e\u003cspan data-path-to-node=\"8,0,2,1,0,0\"\u003eSingle Cell Spatial Org\u003cspan class=\"citation-346 citation-end-346\"\u003eanization of Tumor Microenvironment\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-97\" data-path-to-node=\"8,0,2,2,0\"\u003e\u003cspan data-path-to-node=\"8,0,2,2,0,0\"\u003e\u003cspan class=\"citation-345 citation-end-345\"\u003eAdvances in MRD Detection: Peripheral Blood and Bone Marrow Strategies\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-98\" data-path-to-node=\"8,0,2,3,0\"\u003e\u003cspan data-path-to-node=\"8,0,2,3,0,0\"\u003e\u003cspan class=\"citation-344 citation-end-344\"\u003eMonitoring for Infectious Post-T-Cell-Based Therapy\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-99\" data-path-to-node=\"8,0,2,4,0\"\u003e\u003cspan data-path-to-node=\"8,0,2,4,0,0\"\u003e\u003cspan class=\"citation-343 citation-end-343\"\u003ePredictors of Response and Mechanisms of Relapse\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-112\" data-path-to-node=\"8,1,0\"\u003e\u003cb data-path-to-node=\"8,1,0\" data-index-in-node=\"0\"\u003e\u003cspan class=\"citation-342 citation-end-342\"\u003eTreatment with Novel Agents\/Novel Combinations\/N\u003c\/span\u003eovel Concepts\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"8,1,2\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-101\" data-path-to-node=\"8,1,2,0,0\"\u003e\u003cspan data-path-to-node=\"8,1,2,0,0,0\"\u003eCelMOD (Combinations)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-102\" data-path-to-node=\"8,1,2,1,0\"\u003e\u003cspan data-path-to-node=\"8,1,2,1,0,0\"\u003e1 Line Therapy with Belamaf + Future Options\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-103\" data-path-to-node=\"8,1,2,2,0\"\u003e\u003cspan data-path-to-node=\"8,1,2,2,0,0\"\u003e2 Line Therapy with Belamaf\/Occular Management\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-104\" data-path-to-node=\"8,1,2,3,0\"\u003e\u003cspan data-path-to-node=\"8,1,2,3,0,0\"\u003eBispecific Combinations\/Trispecifics\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-105\" data-path-to-node=\"8,1,2,4,0\"\u003e\u003cspan data-path-to-node=\"8,1,2,4,0,0\"\u003eCART Cells in Earlier Lines\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003e\u003cb data-path-to-node=\"8,2,0\" data-index-in-node=\"0\"\u003eManagement of Complications\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"8,2,2\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-107\" data-path-to-node=\"8,2,2,0,0\"\u003e\u003cspan data-path-to-node=\"8,2,2,0,0,0\"\u003eCIDP Post-Cilta-cel\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-108\" data-path-to-node=\"8,2,2,1,0\"\u003e\u003cspan data-path-to-node=\"8,2,2,1,0,0\"\u003eImmune Effector Cell Associated Secondary Malignancies\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-109\" data-path-to-node=\"8,2,2,2,0\"\u003e\u003cspan data-path-to-node=\"8,2,2,2,0,0\"\u003eBridging Therapies\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-110\" data-path-to-node=\"8,2,2,3,0\"\u003e\u003cspan data-path-to-node=\"8,2,2,3,0,0\"\u003eRelapse Management\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_1205aa4f3b7b4f86-111\" data-path-to-node=\"8,2,2,4,0\"\u003e\u003cspan data-path-to-node=\"8,2,2,4,0,0\"\u003eModulation of the Target Antigen\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43113249472610,"sku":"MED-AMB09587","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/International-Myeloma-Society-Practical-Insights-in-and-Translational-Aspects-of-Novel-Immune-Therapies-in-Multiple-Myeloma-2025-1.jpg?v=1783964497","url":"https:\/\/meducourse.com\/products\/international-myeloma-society-practical-insights-in-and-translational-aspects-of-novel-immune-therapies-in-multiple-myeloma-2025","provider":"Meducourse","version":"1.0","type":"link"}